Abiomed Letter Underscores Questions On FDA’s Clinical Decision Support Guidance

A warning letter from the US FDA to device manufacturer Abiomed highlights industry’s criticism that the agency’s final guidance on clinical decision support software is flawed and oversteps regulatory boundaries.